Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3

Reuters Events 9 December, 2021. 10AM EST, 3PM GMT, 4PM CET. Virtual Event.
Medical affairs teams are challenged by rising costs and accelerated timelines - and hampered by inefficiency throughout the insight gathering process. These breakdowns occur before a single insight is collected: by engaging with the wrong KOLs, medical affairs won't access the right strategic insights while wasting time and effort. Add to this the deafening volume of information that HCPs are being bombarded with, and it's quickly apparent that unless you can gather and implement insights quickly, you've missed your window of opportunity to deliver value to your physicians.

But by using technology and a refined strategy to identify the right experts, engage them in the right venue and obtain key insights in real-time, teams can build a winning strategy while reducing costs and shortening timelines.

In this webinar, you'll learn:

  • How to identify and interact with the best experts for the topics your HCPs need
  • Best practices to effectively engage audiences for optimum insight volume and quality
  • First steps in advanced insight management to deliver value faster to your physicians

Register your place for this exclusive webinar here

You will hear from:

  • Harmony Garges, Chief Medical Officer, ViiV Healthcare
  • Kirk Shepard, Chief Medical Officer OBG, SVP & Head of Global Medical Affairs, Eisai
  • Oscar Segurado, Chief Medical Officer, ASC Therapeutics
  • Lance Hill, CEO, Within3

Tune in live on December 9th 10am EST / 3pm GMT / 4pm CET, to join the Q&A with the panellists

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...